...Pretreatment expression of ERCC1 in localized esophageal and gastroesophageal adenocarcinomas is a marker for outcomes among patients given trimodality therapy that includes oxaliplatin-based chemoradiation, investigators reported from a prospective study.
Fully 58% of the 55 patients studied from the Southwest Oncology Group (SWOG) S0356 trial had tumors expressing a high level of mRNA for ERCC1, a key gene in the repair of platinum- and radiation-induced DNA damage.
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.